Clinical cardiology resource center

Resource Center

Supported by independent educational grants from sanofi-aventis, Bristol-Myers Squibb and Medtronic

Abstracts

Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study.
Enseleit F, Sudano I, Périat D, et al. Eur Heart J. 2012. [Epub ahead of print
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
Bäck M, Yin L, Ingelsson E. Eur Heart J. 2011. [Epub ahead of print]
Effect of adding systematic family history enquiry to cardiovascular disease risk assessment in primary care: a matched-pair, cluster randomized trial.
Qureshi N, Armstrong S, Dhiman P, et al. Ann Intern Med. 2012;156:253-262.
Urinary bisphenol a concentration and risk of future coronary artery disease in apparently healthy men and women.
Melzer D, Osborne NJ, Henley WE, et al. Circulation. 2012;125:1482-1490.
Trans fat, aspirin, and ischemic stroke in postmenopausal women.
Yaemsiri S, Sen S, Tinker L, et al. Ann Neurol. 2012. [Epub ahead of print]
Trends in Cardiovascular Health Metrics and Associations With All-Cause and CVD Mortality Among US Adults.
Yang Q, Cogswell ME, Flanders WD, et al. JAMA. 2012. [Epub ahead of print]
Weighing the Evidence for PCI Decision-Making in Patients with Stable CAD.
Boden WE. Circulation. 2012. [Epub ahead of print]
Comparative Outcomes for Patients Who Do and Do Not Undergo Percutaneous Coronary Intervention for Stable Coronary Artery Disease in New York.
Hannan EL, Samadashvili Z, Cozzens K, et al. Circulation. 2012. [Epub ahead of print]
Stable angina pectoris: the medical management of symptomatic myocardial ischemia.
Parker JD, Parker JO. Can J Cardiol. 2012; 28(Suppl A):S70-80.
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism.
The Einstein-PE Investigators. N Engl J Med. 2012. [Epub ahead of print]
Initial Coronary Stent Implantation With Medical Therapy vs Medical Therapy Alone for Stable Coronary Artery Disease: Meta-analysis of Randomized Controlled Trials.
Stergiopoulos K, Brown DL. Arch Intern Med. 2012;172:312-319.
Disparity of care in the acute care of patients with heart failure.
Diercks DB, Collins SP, Hiestand B, et al. Acad Emerg Med. 2011;18:15-21.
Thirty-day readmission rates for Medicare beneficiaries by race and site of care.
Joynt KE, Orav EJ, Jha AK. JAMA. 2011;305:675-681.
Health behaviors and racial disparity in blood pressure control in the national health and nutrition examination survey.
Redmond N, Baer HJ, Hicks LS. Hypertension. 2011;57:383-389.
Trends and disparities in referral to cardiac rehabilitation after percutaneous coronary intervention.
Aragam KG, Moscucci M, Smith DE, et al. Am Heart J. 2011;161:544-551.e2.
The population effects of the global cardiovascular risk model in United States adults: findings from the National Health and Nutrition Surveys, 2005-2006.
Tattersall MC, Karmali KN, Gangnon RE, et al. J Clin Lipidol. 2011;5:166-172
Gender disparities in the assessment and management of cardiovascular risk in primary care: the AusHEART study.
Turnbull F, Arima H, Heeley E, et al. Eur J Cardiovasc Prev Rehabil. 2011;18:498-503.
Ethnic differences in 1-year mortality among patients hospitalised with heart failure.
Kaul P, McAlister FA, Ezekowitz JA, et al. Heart. 2011;97:1048-1053.
Gender disparities in lipid-lowering therapy among veterans with diabetes.
Vimalananda VG, Miller DR, Palnati M, et al. Womens Health Issues. 2011;21(4 Suppl):S176-181.
Patterns of caregiving among patients hospitalized with cardiovascular disease.
Mosca L, Mochari-Greenberger H, Aggarwal B, et al. J Cardiovasc Nurs. 2011;26:305-311.
Cardiovascular Risk Factor Profiles of Recent Immigrants vs Long-Term Residents of Ontario: A Multi-Ethnic Study.
Chiu M, Austin PC, Manuel DG, et al. Can J Cardiol. 2011. [Epub ahead of print]
Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data.
Vaidya D, Becker DM, Bittner V, et al. BMJ. 2011;343:d5170.
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis.
Singh S, Loke YK, Spangler JG, et al. CMAJ. 2011;183:1359-1366.
Xanthelasmata, arcus corneae, and ischaemic vascular disease and death in general population: prospective cohort study.
Christoffersen M, Frikke-Schmidt R, Schnohr P, et al. BMJ. 2011;343:d5497.
Safety and efficacy of exercise training after coronary stenting in patients with stable coronary artery disease.
Soga Y, Yokoi H, Amemiya K, et al. Circ J. 2011;75:2379-2386.
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
Bavry AA, Khaliq A, Gong Y, et al. Am J Med. 2011;124:614-620.
Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial.
Maron DJ, Boden WE, Spertus JA, et al. J Am Coll Cardiol. 2011;58:131-137.
Quality of Life of Patients With Peripheral Arterial Disease and Chronic Stable Angina.
Wilson WR, Fitridge RA, Weekes AJ, et al. Angiology. 2011. [Epub ahead of print]
Pulse oximetry screening for congenital heart defects in newborn infants (PulseOx): a test accuracy study.
Ewer AK, Middleton LJ, Furmston AT, et al. Lancet. 2011;378:785-794.
Accuracy and prognostic value of American Heart Association: recommended depression screening in patients with coronary heart disease: data from the heart and soul study.
Elderon L, Smolderen KG, Na B, et al. Circ Cardiovasc Qual Outcomes. 2011;4:533-540.
Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events.
Jespersen L, Hvelplund A, Abildstrøm SZ, et al. Eur Heart J. 2011. [Epub ahead of print]
Diseased skeletal muscle a noncardiac source of increased circulating concentrations of cardiac troponin T.
Jaffe AS, Vasile VC, Milone M, et al. J Am Coll Cardiol. 2011;58:1819-1824.
High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden.
Ohlsson C, Barrett-Connor E, Bhasin S, et al. J Am Coll Cardiol. 2011;58:1674-1681.
Comparison of Everolimus- and Paclitaxel-Eluting Stents in Patients With Acute and Stable Coronary Syndromes Pooled Results From the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
Planer D, Smits PC, Kereiakes DJ, et al. JACC Cardiovasc Interv. 2011;4:1104-1115.
Update on the medical treatment of stable angina.
Gayet JL, Paganelli F, Cohen-Solal A. Arch Cardiovasc Dis. 2011;104:536-544
Stable Angina Pectoris: Head-to-Head Comparison of Prognostic Value of Cardiac CT and Exercise Testing.
Dedic A, Genders TS, Ferket BS, et al. Radiology. 2011;261:428-436.
Determination of the cut-off plasma adiponectin level associated with a lower risk of restenosis in patients with stable angina.
Mito T, Miura S, Iwata A, et al. Coron Artery Dis. 2011;22:451-457.
The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease.
Patel PJ, Khera AV, Jafri K, et al. J Am Coll Cardiol. 2011;58:2068-2075.
Multivessel percutaneous coronary intervention in patients with stable angina: a common approach? Lessons learned from the EHS PCI registry.
Bauer T, Möllmann H, Zeymer U, et al. Heart Vessels. 2011. [Epub ahead of print]
Comparison of Outcomes of Patients ?80 Years of Age Having Percutaneous Coronary Intervention According to Presentation (Stable vs Unstable Angina Pectoris/Non-ST-Segment Elevation Myocardial Infarction vs ST-Segment Elevation Myocardial Infarction).
Antonsen L, Jensen LO, Thayssen P, et al. Am J Cardiol. 2011;108:1395-1400.
Harmful Effects of NSAIDs among Patients with Hypertension and Coronary Artery Disease.
Bavry AA, Khaliq A, Gong Y, et al. Am J Med. 2011;124:614-620.
Myocardial Perfusion by Myocardial Contrast Echocardiography and Endothelial Dysfunction in Obstructive Sleep Apnea.
Butt M, Khair OA, Dwivedi G, et al. Hypertension. 2011. [Epub ahead of print]
Quality of care and patient outcomes in critical access rural hospitals.
Joynt KE, Harris Y, Orav EJ, et al. JAMA. 2011;306:45-52.
Coffee consumption and mortality in women with cardiovasculardisease.
Lopez-Garcia E, Rodriguez-Artalejo F, Li TY, et al. Am J Clin Nutr. 2011;94:218-224.
Quality of Life of Patients With Peripheral Arterial Disease and Chronic Stable Angina.
Wilson WR, Fitridge RA, Weekes AJ, et al. Angiology. 2011. [Epub ahead of print]
Mild depression versus C-reactive protein as a predictor of cardiovascular death: a three year follow-up of patients with stable coronary artery disease.
Rallidis LS, Varounis C, Sourides V, et al. Curr Med Res Opin. 2011;27:1407-1413.
Myocardial fractional flow reserve : Its role in guiding PCI in stable coronary artery disease.
Lindstaedt M, Mügge A. Herz. 2011. [Epub ahead of print]
Effect of exercise training on vascular endothelial function in patients with stable coronary artery disease: a randomized controlled trial.
Luk TH, Dai YL, Siu CW, et al. Eur J Cardiovasc Prev Rehabil. 2011. [Epub ahead of print]
Effectiveness of Preprocedural Statin Therapy on Clinical Outcomes for Patients With Stable Coronary Artery Disease After Percutaneous Coronary Interventions.
Ko DT, Wijeysundera HC, Yun L, et al. Circ Cardiovasc Qual Outcomes. 2011. [Epub ahead of print]
Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association (PERGENE) study.
Brugts JJ, de Maat MP, Danser AH, et al. Neth Heart J. 2011. [Epub ahead of print]
Impact of physicians' age on the clinical management of global cardiovascular risk: analysis of the results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitisation Educational Programme.
Tocci G, Ferrucci A, Guida P, et al. Int J Clin Pract. 2011;65:649-657.
Opposing Effects of β Blockers and Angiotensin-Converting Enzyme Inhibitors on Development of New-Onset Diabetes Mellitus in Patients With Stable Coronary Artery Disease.
Vardeny O, Uno H, Braunwald E, et al. Am J Cardiol. 2011;107:1705-1709.
Relation of concentric remodeling to adverse outcomes in patients with stable coronary artery disease (from the Heart and Soul Study).
Berger J, Ren X, Na B, et al. Am J Cardiol. 2011;107:1579-1584.
Summary of AHRQ's Comparative Effectiveness Review of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease.
White CM, Greene L. J Manag Care Pharm. 2011;17:S1-15.
Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention.
Borden WB, Redberg RF, Mushlin AI, et al. JAMA. 2011;305:1882-1889. Erratum in: JAMA. 2011; 305:2418.
Prognostic Usefulness of Free Fatty Acids in Patients With Stable Coronary Heart Disease.
Breitling LP, Rothenbacher D, Grandi NC, et al. Am J Cardiol. 2011. [Epub ahead of print]
First-degree atrioventricular block is associated with heart failure and death in persons with stable coronary artery disease: data from the Heart and Soul Study.
Crisel RK, Farzaneh-Far R, Na B, et al. Eur Heart J. 2011. [Epub ahead of print]
Differential protein biomarker expression and their time-course in patients with a spectrum of stable and unstable coronary syndromes in the Integrated Biomarker and Imaging Study-1 (IBIS-1).
Wykrzykowska JJ, Garcia-Garcia HM, Goedhart D, et al. Int J Cardiol. 2011;149:10-16.
Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease.
Dagenais GR, Lu J, Faxon DP, et al. Circulation. 2011; 123:1492-1500.
Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe.
Cacoub PP, Zeymer U, Limbourg T, et al. Heart. 2011;97:660-667.
Association of episodic physical and sexual activity with triggering of acute cardiac events: systematic review and meta-analysis.
Dahabreh IJ, Paulus JK. JAMA. 2011;305:1225-1233.
Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications.
García Rodríguez LA, Lin KJ, Hernández-Díaz S, et al. Circulation. 2011;123:1108-1115.
Effect of two-day atorvastatin pretreatment on long-term outcome of patients with stable angina pectoris undergoing elective percutaneous coronary intervention.
Veselka J, Zemánek D, Hájek P, et al. Am J Cardiol. 2011;107:1295-1299.
Validation of long-term benefits of bivalirudin versus unfractionated heparin in routine clinical practice after percutaneous coronary intervention.
Vidi VD, Matheny ME, Agarwal V, et al. Am J Cardiol. 2010;106:1234-1240.
Prognostic value of electrocardiographic detection of unrecognized myocardial infarction in persons with stable coronary artery disease: data from the Heart and Soul study.
Kehl DW, Farzaneh-Far R, Na B, Whooley MA. Clin Res Cardiol. 2010 Nov 20. [Epub ahead of print]
High prevalence of intramural coronary infection in patients with drug-resistant cardiac syndrome X: comparison with chronic stable angina and normal controls.
Chimenti C, Sale P, Verardo R, et al. Heart. 2010;96:1926-1931. Epub 2010 Oct 3.
Association of low leptin with cardiovascular events and mortality in patients with stable coronary artery disease: the Heart and Soul study.
Ku IA, Farzaneh-Far R, Vittinghoff E, Zhang MH, Na B, Whooley MA. Atherosclerosis. 2010 Dec 2. [Epub ahead of print]
Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population.
de Lemos JA, Drazner MH, Omland T, et al. JAMA. 2010;304:2503-2512.
Mechanisms underlying the lack of effect of implantable cardioverter-defibrillator therapy on mortality in high-risk patients with recent myocardial infarction: insights from the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT).
Dorian P, Hohnloser SH, Thorpe KE, et al. Circulation. 2010;122:2645-2652. Epub 2010 Dec 6.
Hysterectomy and risk of cardiovascular disease: a population based cohort study.
Ingelsson E, Lundholm C, Johansson AL, Altman D. Eur Heart J. 2011;32:745-750. Epub 2010 Dec 24.
Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study.
Collet JP, Cayla G, Cuisset T, et al. Am Heart J. 2011;161:5-12.
Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study).
Fernandez A, Aboodi MS, Milewski K, Delgado JA, Rodríguez A, Granada JF. Am J Cardiol. 2011;107:6-9.
Stable angina in women: lessons from the National Heart, Lung and Blood Institute-sponsored women's ischemia syndrome evaluation.
Merz CN, Shaw LJ. J Cardiovasc Med (Hagerstown). 2011;12:85-87.
Role of medical versus interventional strategies to prevent coronary events in patients with stable coronary artery disease.
Carbajal EV, Deedwania P. Cardiol Clin. 2011;29:157-165.
Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies.
Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA. Eur Heart J. 2011 Feb 7. [Epub ahead of print]
Effect of cardiac rehabilitation referral strategies on utilization rates: a prospective, controlled study.
Grace SL, Russell KL, Reid RD, et al.; for the Cardiac Rehabilitation Care Continuity Through Automatic Referral Evaluation (CRCARE) Investigators. Arch Intern Med. 2011;171:235-241.
Long-term impact of secondary preventive treatments in patients with stable angina.
Vokó Z, de Brouwer S, Lubsen J, et al. Eur J Epidemiol. 2011 Feb 19. [Epub ahead of print]
Coronary revascularization does not decrease cardiac events in patients with stable ischemic heart disease but might do in those who showed moderate to severe ischemia.
Moroi M, Yamashina A, Tsukamoto K, Nishimura T; for the J-ACCESS Investigators. Int J Cardiol. 2011 Feb 20. [Epub ahead of print]
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels.
Dehghan A, Dupuis J, Barbalic M, et al. Circulation. 2011;123:731-738.
Factors influencing underutilization of evidence-based therapies in women.
Bugiardini R, Yan AT, Yan RT, et al.; on behalf of the Canadian Acute Coronary Syndrome Registry I and II Investigators. Eur Heart J. 2011 Mar 7. [Epub ahead of print]
Influence of aetiology on long-term effects of resynchronization on cardiac structure and function in patients treated with beta-blockers.
Zacà V, Baiocchi C, Gaddi R, et al. J Cardiovasc Med (Hagerstown). 2011;12:227-233.
Cardiac Recovery During Continuous-Flow Left Ventricular Assist Device Support: Some Good News From Across the Atlantic.
Maybaum S. Circulation. 2011 Jan 17. [Epub ahead of print]
Reversal of Severe Heart Failure With a Continuous-Flow Left Ventricular Assist Device and Pharmacological Therapy: A Prospective Study.
Birks EJ, George RS, Hedger M, et al. Circulation. 2011 Jan 17. [Epub ahead of print]
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients.
Rosenberg S, Elashoff MR, Beineke P, et al; PREDICT (Personalized Risk Evaluation and Diagnosis in the Coronary Tree) Investigators. Ann Intern Med. 2010;153:425-434.
Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
Ensrud K, LaCroix A, Thompson JR, et al. Circulation. 2010;122:1716-1724.
Association of features of primary health care with coronary heart disease mortality.
Levene LS, Baker R, Bankart MJ, Khunti K. JAMA. 2010;304:2028-2034
Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.
Storey RF, Bliden KP, Patil SB, et al; ONSET/OFFSET Investigators. J Am Coll Cardiol. 2010;56:185-193.
Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study.
van Melle JP, Bot M, de Jonge P, de Boer RA, van Veldhuisen DJ, Whooley MA. Diabetes Care. 2010;33:2084-2089.
Do major cardiovascular outcomes in patients with stable ischemic heart disease in the clinical outcomes utilizing revascularization and aggressive drug evaluation trial differ by healthcare system?
Chaitman BR, Hartigan PM, Booth DC, et al; Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial investigators. Circ Cardiovasc Qual Outcomes. 2010;3:476-483.
Differential associations between specific depressive symptoms and cardiovascular prognosis in patients with stable coronary heart disease.
Hoen PW, Whooley MA, Martens EJ, Na B, van Melle JP, de Jonge P. J Am Coll Cardiol. 2010;56:838-844.
The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease.
Stone PH, Chaitman BR, Stocke K, Sano J, DeVault A, Koch GG. J Am Coll Cardiol. 2010;56:934-942
Strategies in stable ischemic heart disease: lessons from the COURAGE and BARI-2D trials.
Fernandez SF, Boden WE. Curr Atheroscler Rep. 2010;12:423-431.
Gender differences in the treatment of chronic ischemic heart disease: prognostic implications.
Ciambrone G, Kaski JC. Fundam Clin Pharmacol. 2010;24:707-710
Controversies in cardiovascular medicine: Chronic stable coronary artery disease: drugs vs. revascularization
Simoons ML, Windecker S. Eur Heart J. 2010;31:530-541.
Management of stable coronary artery disease
Pfisterer ME, Zellweger MJ, Gersh BJ. Lancet. 2010;375:763-772.
Ranolazine: an anti-anginal drug with further therapeutic potential.
Reffelmann T, Kloner RA. Expert Rev Cardiovasc Ther. 2010;8:319-329. Review.
Inadequate control of heart rate in patients with stable angina: results from the European heart survey
Daly CA, Clemens F, Sendon JL, et al. Postgrad Med J. 2010;86:212-217.
Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial)
Parodi G, Migliorini A, Valenti R, et al. Am J Cardiol. 2010;105:1053-1059.
Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study
Bertrand ME, Ferrari R, Remme WJ, et al. Am Heart J. 2010;159:795-802.
Is there a Failure to Optimize theRapy in anGina pEcToris (FORGET) study?
Elder DH, Pauriah M, Lang CC, et al. QJM. 2010;103:305-310.